In silico Investigation of Lon Protease as a Promising Therapeutic Target

 

 Permissions and Reprints

Abstract

Considering the widespread occurrence of antibiotic resistance, the need for new therapeutic strategies is inevitable. Bacterial proteases are a broad set of enzymes that play a vital role in cell survival, stress response, and pathogenicity. This in silico study was aimed to focus on the crucial role of Lon protease in the regulation of toxin-antitoxin systems in E. coli and to design inhibitory peptides against the action of this protease. With the help of relevant servers and softwares, the communication network, the evolutionary history, and the interaction of Lon with the corresponding antitoxins were examined, following which the inhibitory peptides were designed against these interactions. The results showed that Lon protease plays a central role in the control of these systems and is a conserved protein, especially among the Enterobacteriaceae family. The docking results of the designed peptides with the Lon protease were significant. This study showed that Lon protease may have the characteristics of a new therapeutic target.

Publication History

Received: 25 September 2021

Accepted: 30 November 2021

Article published online:
18 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Reverter M. et al. Aquaculture at the crossroads of global warming and antimicrobial resistance 2020; 11: 1-8
  PubMed
• 2 Hendriksen RS. et al. Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage 2019; 10 p 1-12
  PubMed
• 3 Boolchandani M, D’Souza AW, Dantas GJNRG. Sequencing-based methods and resources to study antimicrobial resistance 2019; 20: 356-370
  PubMed
• 4 Spaulding CN. et al. Precision antimicrobial therapeutics: the path of least resistance? 2018; 4: 1-7
  PubMed
• 5 Arends J. et al. An integrated proteomic approach uncovers novel substrates and functions of the Lon protease in Escherichia coli 2018; 18: 1800080
  PubMed
• 6 Tsilibaris V, Maenhaut-Michel G, Van Melderen L.J.R.i.m. Biological roles of the Lon ATP-dependent protease 2006; 157: 701-713
  PubMed
• 7 Page R, Peti W.J.N.c.b. Toxin-antitoxin systems in bacterial growth arrest and persistence 2016; 12: 208-214
  PubMed
• 8 Song S, Wood T.K.J.A.b. Toxin/antitoxin system paradigms: toxins bound to antitoxins are not likely activated by preferential antitoxin degradation 2020; 4: 1900290
  PubMed
• 9 Ghafourian S. et al. Toxin-antitoxin systems: classification, biological function and application in biotechnology 2014; 16: 9-14
  PubMed
• 10 Ezraty B. et al. Oxidative stress, protein damage and repair in bacteria 2017; 15: 385
  PubMed
• 11 Cunningham AD, Qvit N, Mochly-Rosen D.J.C.o.i.s.b. Peptides and peptidomimetics as regulators of protein–protein interactions 2017; 44: 59-66
  PubMed
• 12 Waterhouse AM. et al. Jalview Version 2—a multiple sequence alignment editor and analysis workbench 2009; 25: 1189-1191
  PubMed
• 13 Finn RD. et al. The Pfam protein families database: towards a more sustainable future 2016; 44: D279-D285
  PubMed
• 14 Kumar S. et al. MEGA X: molecular evolutionary genetics analysis across computing platforms 2018; 35: 1547-1549
  PubMed
• 15 Yamaguchi Y, Inouye MJNRM. Regulation of growth and death in Escherichia coli by toxin–antitoxin systems 2011; 9: 779-790
  PubMed
• 16 Kozakov D. et al. The ClusPro web server for protein–protein docking 2017; 12: 255
  PubMed
• 17 Laskowski RA, Swindells MB. LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. 2011. ACS Publications;
  CrossrefGoogle Scholar
• 18 Sedan Y. et al. Peptiderive server: derive peptide inhibitors from protein–protein interactions 2016; 44: W536-W541
  PubMed
• 19 Lamiable A. et al. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex 2016; 44: W449-W454
  PubMed
• 20 DeLano W.L.J.C.N.o.p.c. Pymol: An open-source molecular graphics tool. 2002; 40: 82-92
  PubMed
• 21 Culp E, Wright G.D.J.T.J.o.a. Bacterial proteases, untapped antimicrobial drug targets 2017; 70: 366-377
  PubMed
• 22 Narimisa N. et al. Effects of sub-inhibitory concentrations of antibiotics and oxidative stress on the expression of type II toxin-antitoxin system genes in Klebsiella pneumoniae 2020; 21: 51-56
  PubMed
• 23 Magana M. et al. The value of antimicrobial peptides in the age of resistance. 2020
  PubMed
• 24 Kazemzadeh-Narbat M. et al. Strategies for antimicrobial peptide coatings on medical devices: a review and regulatory science perspective 2021; 41: 94-120
  PubMed
• 25 Wu AY, Kamruzzaman M, Iredell J.R.J.P.o. Specialised functions of two common plasmid mediated toxin-antitoxin systems, ccdAB and pemIK, in Enterobacteriaceae 2020; 15: e0230652
  PubMed
• 26 Xu J. et al. Functional investigation of the chromosomal ccdAB and hipAB operon in Escherichia coli Nissle 1917 2020; 104: 6731-6747
  PubMed
• 27 Wen Y. et al. Toxin–Antitoxin systems: their role in persistence, biofilm formation, and pathogenicity 2014; 70: 240-249
  PubMed
• 28 Babin BM. et al. Leveraging peptide substrate libraries to design inhibitors of bacterial Lon protease 2019; 14: 2453-2462
  PubMed
• 29 Mohammadzadeh R. et al. In silico insight into the dominant type II toxin–antitoxin systems and Clp proteases in Listeria monocytogenes and designation of derived peptides as a novel approach to interfere with this system 2020; 26: 613-623
  PubMed
• 30 Sundar S. et al. In Silico Derived Peptides for Inhibiting the Toxin–Antitoxin Systems of Mycobacterium tuberculosis: Basis for Developing Peptide-Based Therapeutics 2019; 25: 1467-1475
  PubMed

• Supplementary Material